Why the study?
Little was known regarding the rate of anthracycline-related acute and chronic cardiotoxicity and adherence to cardiac monitoring recommendations among cancer patients.
What is the incidence of cardiotoxicity and adherence to cardiac monitoring guidelines among cancer patients treated with anthracyclines?
What is the incidence of cardiotoxicity and adherence to cardiac monitoring guidelines among cancer patients treated with anthracyclines?
There is a high incidence of anthracycline-induced cardiotoxicity and poor adherence to ASCO cardiac monitoring guidelines in cancer patients.
Answers are grounded in this paper and cite their sources.
High cardiotoxicity incidence with low monitoring adherence signals need for better surveillance; leaves open optimal real-world strategies.
PURPOSE: Cardiotoxicity is a common complication associated with anthracyclines. Little is known regarding the rate of anthracyclines-related acute and chronic cardiotoxicity and adherence to cardiac monitoring recommendations among cancer patients. PATIENTS AND METHODS: A single-centre retrospective cohort study was conducted from 2015 to 2018 on patients with cancer, 18 years of age and older, on anthracyclines without a history of cardiovascular diseases. Data on demographic information, comorbidities, cardiovascular events, monitoring parameters, and treatment details were obtained. The primary outcome was the incidence of anthracyclines-related cardiotoxicity both acute and chronic. The secondary outcome was to determine adherence to guideline recommendations for monitoring anthracyclines-related cardiotoxicity based on the American Society of Clinical Oncology clinical practice guidelines. Analyses included descriptive statistics and logistic regression. Institutional review board approval was obtained. RESULTS: In 235 patients identified, 28.9% developed cardiotoxicity, of which 27.2% were acute, while chronic cardiotoxicity was observed in 8.9% of subjects. Patients who received optimal cardiac monitoring had a statistically significant higher odds of developing cardiotoxicities (odds ratio=2.65, confidence interval=1.32-5.33). The risk of cardiotoxicity was higher in subjects with a history of diabetes mellitus, those using daunorubicin, and concomitant filgrastim use. Adherence to guideline recommendations was only achieved in 25.1% of the population. Echocardiography was the most common monitoring method used. CONCLUSION: In this study, there was a high incidence of anthracyclines cardiotoxicity and poor compliance with cardiac monitoring recommendations for cancer patients on anthracyclines, which underscores acute and chronic cardiotoxicity in this population.
No takes yet. Share an insight, caveat, or question.
Alkofide et al. (2021) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: